Emergent BioSolutions Inc. (EBS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Emergent BioSolutions Inc. (EBS) Healthcare & Pipeline Overview

Emergent BioSolutions Inc. provides specialized preparedness and response solutions for public health threats, focusing on vaccines, therapeutics, and devices. With a portfolio addressing anthrax, smallpox, and opioid overdose, the company serves government and commercial markets, navigating a complex regulatory landscape within the specialty pharmaceutical sector.

What Is the Investment Thesis for EBS?

Emergent BioSolutions Inc. presents a mixed investment case. The company's focus on public health threats provides a degree of revenue stability through government contracts, particularly for products like BioThrax and ACAM2000. However, the company's negative profit margin of -1.3% and high beta of 2.36 indicate significant financial risk and market volatility. Growth catalysts include the development and potential approval of new products like AP003 (Naloxone nasal spray) and AV7909 (anthrax vaccine). The company's contract development and manufacturing services also offer growth opportunities. Investors should closely monitor the company's ability to improve profitability, manage its debt, and successfully navigate the regulatory landscape.

Based on FMP financials and quantitative analysis

EBS Key Highlights

Market capitalization of $249M, reflecting its position as a smaller player in the specialty pharmaceutical market.

• Gross margin of 44.4%, indicating a solid ability to control production costs, though this needs to translate to overall profitability.
• Beta of 2.36, suggesting high volatility compared to the broader market, potentially due to its reliance on government contracts and regulatory approvals.
• Focus on public health threats provides a degree of revenue stability through government contracts.
• 900 employees, reflecting a significant operational footprint for its market capitalization.

Who Are EBS's Competitors?

EBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EBS's Key Strengths?

Specialized expertise in public health threats.

• Established relationships with government agencies.
• Portfolio of approved vaccines and therapeutics.
• Contract development and manufacturing capabilities.

What Are EBS's Weaknesses?

Negative profit margin.

• High debt levels.
• Reliance on government contracts.
• Exposure to regulatory risks.

What Could Drive EBS Stock Higher?

Potential FDA approval of AP003 (Naloxone multidose nasal spray) within the next 12-18 months.

• Continued government contracts for BioThrax and ACAM2000.
• Expansion of contract development and manufacturing services (CDMO) business.

What Are the Key Risks for EBS?

Financial-distress signal — its Altman Z-Score of 0.77 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-1.6%) — the business is not currently generating profit on shareholder capital.
• Regulatory setbacks for new product approvals.
• Competition from larger pharmaceutical companies.
• Changes in government funding priorities for biodefense.
• High debt levels impacting financial flexibility.

What Are the Growth Opportunities for EBS?

• Expansion of NARCAN Sales: The market for opioid overdose reversal medications is expanding due to the ongoing opioid crisis. Emergent BioSolutions can capitalize on this by increasing the sales and distribution of NARCAN nasal spray. The opioid overdose market is estimated to reach several billion dollars annually, providing a substantial growth opportunity. Timeline: Ongoing.
• Development and Approval of New Products: Emergent BioSolutions has several products in its pipeline, including AP003 (Naloxone multidose nasal spray) and AV7909 (anthrax vaccine). Successful development and regulatory approval of these products could significantly boost revenue. The market for new vaccines and therapeutics is substantial, with potential revenues in the hundreds of millions of dollars per product. Timeline: 2-5 years.
• Growth in Contract Development and Manufacturing Services (CDMO): The CDMO market is growing as pharmaceutical companies increasingly outsource manufacturing and development activities. Emergent BioSolutions can expand its CDMO business by leveraging its expertise in drug substance and product manufacturing. The global CDMO market is projected to reach over $100 billion by 2026. Timeline: Ongoing.
• Government Contracts for Biodefense Products: Governments worldwide are investing in biodefense preparedness, creating opportunities for Emergent BioSolutions to secure contracts for its vaccines and therapeutics. The market for biodefense products is driven by concerns over bioterrorism and emerging infectious diseases. Timeline: Ongoing.
• International Expansion: Emergent BioSolutions primarily operates in the United States. Expanding its operations to international markets could provide significant growth opportunities. The global market for vaccines and therapeutics is substantial, with potential revenues in the billions of dollars. Timeline: 3-5 years.

What Are EBS's Competitive Advantages?

• Specialized expertise in biodefense and emerging infectious diseases.
• Long-standing relationships with government agencies.
• Proprietary manufacturing capabilities for vaccines and therapeutics.
• Regulatory approvals and market exclusivity for key products.

What Does EBS Do?

Emergent BioSolutions Inc. was founded in 1998 with a mission to safeguard and enhance public health by providing specialized solutions for public health threats (PHTs). Headquartered in Gaithersburg, Maryland, the company has evolved into a key player in the biodefense and emerging infectious disease space. Its core business revolves around developing, manufacturing, and delivering vaccines, therapeutics, and devices that address accidental, deliberate, and naturally occurring PHTs. Key products include BioThrax (anthrax vaccine), ACAM2000 (smallpox vaccine), and NARCAN (naloxone nasal spray for opioid overdose). The company also offers contract development and manufacturing services (CDMO), leveraging its expertise in drug substance and product manufacturing. Emergent BioSolutions serves a diverse customer base, including government agencies like the U.S. Department of Health and Human Services, as well as commercial entities. The company's strategic focus on public health preparedness positions it within a niche market, requiring continuous innovation and adaptation to evolving threats.

What Products and Services Does EBS Offer?

• Develops and manufactures vaccines for diseases like anthrax and smallpox.
• Produces therapeutics for botulism and other public health threats.
• Offers NARCAN nasal spray for emergency treatment of opioid overdose.
• Provides contract development and manufacturing services (CDMO) to other pharmaceutical companies.
• Develops and manufactures devices, such as auto-injectors, for emergency medical use.
• Focuses on preparedness and response solutions for chemical, biological, radiological, nuclear, and explosive (CBRNE) threats.

How Does EBS Make Money?

• Develops and manufactures vaccines, therapeutics, and devices for public health threats.
• Sells products to government agencies and commercial customers.
• Provides contract development and manufacturing services (CDMO) to other pharmaceutical companies.
• Secures government contracts for biodefense preparedness.

What Industry Does EBS Operate In?

Emergent BioSolutions Inc. operates within the specialty pharmaceutical and biodefense industry, a sector characterized by high regulatory hurdles and significant government involvement. The market for vaccines and therapeutics addressing public health threats is driven by government preparedness initiatives and concerns over emerging infectious diseases. The competitive landscape includes both large pharmaceutical companies and smaller, specialized players. Emergent BioSolutions differentiates itself through its focus on public health threats and its contract development and manufacturing services. The industry is subject to evolving regulatory requirements and technological advancements, requiring companies to invest in research and development and maintain strong relationships with government agencies.

Who Are EBS's Key Customers?

• U.S. Department of Health and Human Services (HHS)
• Other government agencies
• Hospitals and healthcare providers
• Commercial pharmaceutical companies (for CDMO services)

Company Profile

Emergent BioSolutions Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Gaithersburg, US. The company is led by CEO Joseph C. Papa Jr.. EBS has traded publicly since 2006.

Return on equity for Emergent BioSolutions Inc. stands at -1.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 33.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.29 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.1%, the inverse of the P/E and a quick read on earnings relative to price.

EBS Valuation & Market Position

With a $249M market cap, Emergent BioSolutions Inc. sits in the micro-cap segment of the market. Relative to its peer group, EBS's quantitative score of 30/100 is below the peer average of 74/100.

Quarterly Financial Performance: Emergent BioSolutions Inc.

Revenue for Emergent BioSolutions Inc. came in at $234.3M during Q2 2026, a 50.1% improvement versus the preceding quarter. The company recorded a net loss of $180.2M, with diluted EPS of $-3.49. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, EBS averaged $-0.89 in diluted EPS.

Emergent BioSolutions Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.77 places it in the distress zone, a signal of elevated financial risk.

Emergent BioSolutions Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 247.8% above estimates on average.

Wall Street analysts project Emergent BioSolutions Inc. revenue of about $655.5M for fiscal 2026, with EPS near $0.36.

Over the past six months, Emergent BioSolutions Inc. insiders filed 30 SEC Form 4 transactions — 12 sales and 18 purchases. On net that is roughly 256K shares acquired (about $202K) — insiders putting money in tends to read as conviction.

EBS Financials

EBS Latest News

EBS Analyst Consensus

EBS MoonshotScore

EBS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources